KRYS

+ Watchlist + Portfolio

Krystal Biotech, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $343.34
52-Week Range: $136.73 – $382.54
Market Cap: $9.98B
P/E (TTM): 42.29
EPS (TTM): 7.97
Dividend Yield: —

Advanced Metrics

Price/Book: 7.77
PEG Ratio: —
Return on Equity: 20.12%
Return on Assets: 9.37%
Gross Margin: 94.64%
Operating Margin: 49.00%
Profit Margin: 54.82%
Current Ratio: 8.32
Debt/Equity: 0.01
Total Debt: $8.85M
Free Cash Flow: $151.74M
Revenue Growth: 24.10%
Earnings Growth: 38.80%
Enterprise Value: $9.33B

KRYS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$50.70M	$290.51M	$389.13M
Cost of Revenue	$0.00	$3.09M	$20.06M	$23.05M
Gross Profit	$0.00	$47.60M	$270.45M	$366.08M
Research & Development	$42.46M	$46.43M	$53.58M	$58.05M
Selling, General & Admin	$77.73M	$98.29M	$113.63M	$146.74M
Operating Expenses	$120.20M	$144.72M	$167.21M	$204.79M
Operating Income	-$120.20M	-$97.12M	$103.25M	$161.29M
EBITDA	-$116.81M	-$91.21M	$109.96M	$167.85M
Pretax Income	-$139.97M	$12.90M	$95.36M	$189.47M
Income Tax	$0.00	$1.97M	$6.20M	-$15.36M
Net Income	-$139.97M	$10.93M	$89.16M	$204.83M
Diluted EPS	-5.49	0.39	3.00	6.84
Diluted Shares	25.49M	27.75M	29.74M	29.95M

KRYS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$161.90M	$358.33M	$344.87M	$496.30M
Receivables	$0.00	$42.04M	$104.75M	$127.42M
Inventory	$0.00	$6.99M	$26.51M	$40.48M
Current Assets	$383.78M	$587.91M	$742.04M	$1.02B
Total Assets	$558.45M	$818.36M	$1.06B	$1.33B
Current Liabilities	$28.85M	$33.09M	$102.00M	$102.94M
Total Debt	$8.93M	$8.09M	$7.26M	$9.34M
Total Liabilities	$36.22M	$39.71M	$109.46M	$114.23M
Retained Earnings	-$280.76M	-$269.83M	-$180.67M	$24.16M
Shareholders' Equity	$522.23M	$778.64M	$946.38M	$1.22B
Working Capital	$354.93M	$554.82M	$640.05M	$921.66M

KRYS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$100.57M	-$88.80M	$123.42M	$200.87M
Capital Expenditure	-$52.98M	-$11.80M	-$4.24M	-$11.95M
Free Cash Flow	-$153.55M	-$100.60M	$119.18M	$188.91M
Depreciation & Amortisation	$3.38M	$5.91M	$6.71M	$6.55M
Stock-Based Compensation	$33.23M	$39.93M	$49.13M	$54.51M
Investing Cash Flow	-$114.08M	$82.64M	-$163.44M	-$58.42M
Financing Cash Flow	$35.35M	$202.75M	$27.01M	$8.71M
Net Change in Cash	-$179.31M	$196.58M	-$13.01M	$151.15M

KRYS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$88.18M	$96.04M	$97.80M	$107.11M	$116.36M
Cost of Revenue	$5.03M	$7.17M	$4.26M	$6.59M	$6.32M
Gross Profit	$83.16M	$88.88M	$93.54M	$100.51M	$110.03M
Research & Development	$14.26M	$14.41M	$14.59M	$14.79M	$15.33M
Selling, General & Admin	$32.65M	$35.16M	$37.58M	$41.45M	$41.01M
Operating Expenses	$46.90M	$49.57M	$52.16M	$56.24M	$56.34M
Operating Income	$36.25M	$39.31M	$41.37M	$44.27M	$53.69M
EBITDA	$37.89M	$40.85M	$42.99M	$46.03M	$55.41M
Pretax Income	$43.60M	$46.77M	$47.97M	$51.13M	$61.44M
Income Tax	$7.86M	$8.44M	-$31.40M	-$269.00K	$5.51M
Net Income	$35.73M	$38.33M	$79.36M	$51.40M	$55.93M
Diluted EPS	1.20	1.29	2.66	1.70	1.83
Diluted Shares	29.87M	29.75M	29.83M	30.25M	30.51M

KRYS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$308.77M	$353.83M	$392.60M	$496.30M	$501.31M
Receivables	$103.26M	$111.44M	$129.63M	$127.42M	$127.02M
Inventory	$29.94M	$31.04M	$37.63M	$40.48M	$42.65M
Current Assets	$766.80M	$841.35M	$925.65M	$1.02B	$1.02B
Total Assets	$1.07B	$1.14B	$1.24B	$1.33B	$1.40B
Current Liabilities	$79.49M	$86.90M	$91.27M	$102.94M	$107.80M
Total Debt	$9.66M	$9.68M	$9.51M	$9.34M	$9.11M
Total Liabilities	$89.74M	$97.75M	$102.22M	$114.23M	$120.24M
Retained Earnings	-$144.94M	-$106.60M	-$27.24M	$24.16M	$80.09M
Shareholders' Equity	$984.67M	$1.04B	$1.14B	$1.22B	$1.28B
Working Capital	$687.31M	$754.45M	$834.38M	$921.66M	$911.94M

KRYS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$30.97M	$52.73M	$39.66M	$77.51M	$80.38M
Capital Expenditure	-$6.20M	-$1.90M	-$1.70M	-$2.14M	-$7.15M
Free Cash Flow	$24.77M	$50.83M	$37.95M	$75.37M	$73.23M
Depreciation & Amortisation	$1.63M	$1.54M	$1.61M	$1.76M	$1.73M
Stock-Based Compensation	$13.48M	$14.12M	$13.15M	$13.76M	$13.61M
Investing Cash Flow	-$54.77M	-$10.53M	-$4.29M	$11.16M	-$63.58M
Financing Cash Flow	-$12.47M	$1.80M	$3.71M	$15.67M	-$10.46M
Net Change in Cash	-$36.27M	$44.00M	$39.08M	$104.34M	$6.34M

Market Snapshot

About

Krystal Biotech is a commercial-stage gene therapy company developing treatments for serious diseases with high unmet medical need. The company's lead product, Vyjuvek, is the first topical gene therapy approved by the FDA for the treatment of dystrophic epidermolysis bullosa, a rare genetic skin disorder. Krystal's proprietary platform technology enables gene delivery through skin application.